South San Francisco, United States
Pliant Therapeutics is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutics for the treatment of fibrotic diseases. With a commitment to driving innovative science to address areas of unmet medical need, Pliant aims to transform the lives of patients and individuals affected by fibrotic diseases. The company harnesses the therapeutic potential of integrin biology and TGF-β modulation to develop drug candidates targeted at halting or reversing fibrotic diseases.
Pliant is based in South San Francisco, California, a pivotal location in the biotechnology landscape, and has been recognized as a Best Place to Work by the San Francisco Business Times in 2023. As strong proponents of diversity, equity, and inclusion, the company upholds an evolving and ongoing commitment to these initiatives and is an equal opportunity employer.
The company recently secured a significant $287.50M Post-IPO Equity investment on 24th January 2023, further fueling its mission to deliver best-in-class treatments for fibrotic diseases. With its steadfast dedication and groundbreaking strides in fibrotic disease treatments, Pliant Therapeutics stands at the forefront of biopharmaceutical innovation.
For more information on Pliant Therapeutics and its pioneering work in the treatment of fibrotic diseases, visit www.PliantRx.com.
Applied Molecular Transport
